June 2026
Corporate
NetraMark releases June 2026 Investor Presentation
Updated corporate overview with proven Phase 2 results, expanded pipeline, and C$10.4B addressable market.
Read on SEDAR+Newsroom
News & press releases.
Material announcements, scientific publications, and corporate milestones from NetraMark Holdings.
May 2026
Regulatory
Publication of HALO/ELSA FDA Regulatory Defensibility Framework
Five-component Regulatory Defensibility Index designed for the FDA's emerging AI-native review environment.
Read on SEDAR+Dec 2025
Science
Peer-reviewed publication in npj Digital Medicine (Nature portfolio)
NetraAI's explainable patient subpopulation discovery method validated in the open literature.
Read on SEDAR+Oct 2025
Partnership
Worldwide Clinical Trials MSA executed; QA process completed
NetraAI embedded in WCT Phase 2/3 bids across CNS and oncology programs.
Read on SEDAR+Full release archive available on SEDAR+.